WHY IS END-OF-LIFE SPENDING SO HIGH? EVIDENCE FROM CANCER PATIENTS

Dan Zeltzer, Liran Einav, Amy Finkelstein, Tzvi Shir, Salomon M. Stemmer, Ran D. Balicer

Research output: Contribution to journalArticlepeer-review

Abstract

We study the sources of high end-of-life spending for cancer patients. Even among patients with similar initial prognoses, spending in the year postdiagnosis is over twice as high for those who die within the year than those who survive. Elevated spending on decedents is predominantly driven by higher inpatient spending, particularly low-intensity admissions. However, most such admissions do not result in death, making it difficult to target spending reductions. Furthermore, end-of-life spending is substantially more elevated for younger patients, compared to older patients with similar prognoses. Results highlight sources of high end-of-life spending without revealing any natural “remedies.”

Original languageEnglish
Pages (from-to)511-527
Number of pages17
JournalReview of Economics and Statistics
Volume105
Issue number3
DOIs
StatePublished - 1 May 2023

Keywords

  • Abusive
  • Aggressive. Cyberbul lying
  • Bengali
  • Hate: Sped
  • Low- resource Language
  • Toxic Comment

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Economics and Econometrics

Fingerprint

Dive into the research topics of 'WHY IS END-OF-LIFE SPENDING SO HIGH? EVIDENCE FROM CANCER PATIENTS'. Together they form a unique fingerprint.

Cite this